B R I N G I N G D E a L S T O L I F E

* BROCHURE2017 3RD ANNUAL

7 - 8 F E B R U A R Y 2017 | ETC. VENUES, 155 BISHOPSGATE | LONDON

+ + + 40+ 525 100 200 SHOWCASES EXECUTIVES SPEAKERS INVESTORS

B R I N G I N G D E A L S T O L I F E

LEAD PARTNERS PLATINUM PARTNER

GOLD PARTNERS

SILVER PARTNERS

EUROPEAN PATENT AND TRADE MARK ATTORNEYS WELCOME

Dear Colleague,

We’re delighted to bring you the 3rd annual Biotech and Money / Medtech and Money London conference. WHAT’S NEW IN 2017? With our relentless focus on quality peer-2-peer discussion, high level networking and partnering, • EXCLUSIVE LAUNCH OF unique formats and a vetted, high-calibre LIFE SCIENCE INVESTOR audience, we bring together the people that matter to the future of healthcare and life science PERCEPTION REPORT (P.3) funding, finance, investment and deal making.

For 2017 we’re excited to announce a number of new additions to the content and formats that you are used to seeing at this flagship investment • LAUNCH OF CO-LOCATED conference. It’s a packed two days. MEDTEX CEO FORUM (P.4) AND MEDTECH CONFERENCE (P.11) We’ve also expanded our international reach by bringing our US and EU network to bear on the programme, ensuring we garner the experience and best practice from around the globe. • 40+ INV€$TABLE SHOWCASE Our mission remains one of delivering a conference of unparalleled seniority and PRESENTATIONS FROM UK , US relevance, providing you with the solutions to AND EUROPE’S FINEST PUBLIC further your business needs in 2017. AND PRIVATE BIOTECH AND MEDTECH COMPANIES (P.15) Thank you for joining us and we wish you an incredible event. • 8 INDEPTH ROUNDTABLE Terence O’Dwyer Neil Darkes DISCUSSIONS WITH REAL Co-CEO Co-CEO PRACTICAL OUTCOMES (P.4) PS. Access onsite Wifi through the network etcvenues with password wifi8027

PPS. View the venue floor on page 22. • MORE EUROPEAN AND US INVESTORS, COMPANIES AND PHARMA THAN EVER BEFORE

1 WHAT MAKES US DIFFERENT

KEYNOTE PANELS WITH LEADING LIFE SCIENCE FUNDS INSPIRATIONAL, THOUGHT PROVOKING AND HIGH LEVEL

PANEL DISCUSSIONS ON KEY LIFECYCLE AREAS • EXCLUSIVE LAUNCH OF DEBATE AROUND SEED, EARLY AND GROWTH TACTICS LIFE SCIENCE INVESTOR PERCEPTION REPORT (P.3) ‘ANATOMY OF...’ CASE STUDY DISCUSSIONS COMPARE AND CONTRAST THE APPROACHES OF SUCCESSFUL COMPANIES

• LAUNCH OF CO-LOCATED MEDTEX CEO FORUM (P.4) AND BLUE SKY PLENARY ‘OUTLOOK’ SESSIONS MEDTECH CONFERENCE (P.11) PROVIDING EXECUTIVE FORESIGHT FOR THE YEAR AHEAD

CHATHAM HOUSE RULE LISTED CEO FORUMS PEER-TO-PEER DEBATE BETWEEN PUBLIC EXECS AND INVESTORS

A TRULY INTERNATIONAL CONFERENCE

• 8 INDEPTH ROUNDTABLE PARTICIPATION FROM UK, EUROPE AND US DISCUSSIONS WITH REAL PRACTICAL OUTCOMES (P.4) ‘INVESTABLE’ SHOWCASE PRESENTATIONS OVER 40 INNOVATIVE BIOTECH AND MEDTECH COMPANIES

EXHIBITION-FREE NETWORKING DISTRACTION-FREE, HIGH LEVEL INTERACTIONS

PRE-EVENT ONLINE 1-2-1 PARTNERING SYSTEM ARRANGE ONSITE MEETINGS AND DO BUSINESS IN PRIVATE

2 FEBRUARY 2017 FEBRUARY TH Co-CEO, Biotech and Money Biotech Co-CEO, Science Editor, Financial Times Financial Times Editor, Science

Reporter, BioPharm Insight, Mergermarket Group BioPharm Insight, Mergermarket Reporter, Head of Life Sciences, EY Sciences, Head of Life Managing Director, Forbion Capital Partners Partners Capital Forbion Managing Director,

OPENING KEYNOTE PANEL: KEYNOTE OPENING CAPITAL CONSISTENT AND PATIENT OF BREEDS NEW KEYNOTE PANEL: PANEL: KEYNOTE FLOW CAPITAL US AND EU UK, NATION(S): THE OF STATE EXCLUSIVE LAUNCH OF BIOTECH AND MONEY INVESTOR PERCEPTION REPORT PERCEPTION INVESTOR MONEY AND BIOTECH OF LAUNCH EXCLUSIVE WELCOME REMARKS WELCOME LOOKING BEYOND ‘BEYOND BORDERS’ ‘BEYOND BEYOND LOOKING Neil Darkes, Neil Darkes, CIO, Touchstone Innovations CIO, Touchstone Vice President, Corporate Business Development, Eli Lilly & Co. & Co. Eli Lilly Development, Business Corporate President, Vice CEO, Syncona Partners CEO, Syncona Co-CEO and Co-Founder, Biotech and Money and Money Biotech Co-CEO and Co-Founder, Managing Partner, SV Life Sciences SV Life Managing Partner, Managing Partner, TVM Capital Life Science Life Capital TVM Managing Partner, Partner, F-Prime Capital F-Prime Capital Partner, Co-Chairman and Founder, Mann Bioinvest Mann Bioinvest Founder, Co-Chairman and Clive Cookson, Cookson, Clive Managing Partner, Abingworth Abingworth Managing Partner, Fiona Barry, Fiona Barry, DAY ONE - TUESDAY 7 TUESDAY - ONE DAY

MORNING REFRESHMENTS MORNING REGISTRATION AND BREAKFAST AND REGISTRATION

9.50

9.10 9.00

10.30 10.40 Martin Murphy, Bingham, Kate Moderator: Moderator: Jim Mellon, Nigel Pitchford, will influence the future success and prosperity of the UK entrepeneurial finance ecosystem, including how the UK including ecosystem, finance UK entrepeneurial of the and prosperity success the future will influence the new represent will executives Chiefly sector. Science in the Life and innovation growth the stimulation, ensure can void. fill the current can this approach and how capital consistent of patient capital; breed In this high level discussion we assemble a panel of senior investment executives who will debate the key issues that issues the key who will debate executives investment a panel of senior assemble we discussion In this high level Alex Pasteur, Alex Erwin, Johnston Tim Haines, Sander Slootweg, Hubert Birner, private investor appetite in the year ahead. in the year appetite investor private Moderator: As the healthcare sector continues to develop favourably what can the UK and Europe be doing better (or more of) to of) to (or more be doing better the UK and Europe what can favourably develop to continues sector As the healthcare to stage the share fund Executives venture UK, EU and US Prominent flow?. capital or increased sustained see a more and office family on institutional, their views plus share investment, science of life challenges and outline their views David MacMurchy, David MacMurchy, U.K. in stepping up in this space and why do investors reward operations?. These are just some of the themes to be some of the themes to just These are operations?. reward and why do investors up in this space U.K. in stepping ‘Beyond report of their Biotechnology the 2016 release by EY, as an extension in this position piece discussed Borders’. When do successful Biotechs start their operational journey? What can we draw from the US market to support the support to the US market from draw we What can journey? their operational start Biotechs When do successful Terry O’Dwyer, O’Dwyer, Terry that can be leveraged by key stakeholders for their own strategic decision making. strategic their own for stakeholders by key be leveraged that can a summary of our findings. it with you share to proud very are We strategy. insight powerful at the same time providing while this gap in knowledge, address will hopefully and report This survey The mission of this survey and report is to create unique and actionable insight into investor attitudes, biases and attitudes, biases investor insight into unique and actionable create is to report and of this survey The mission their decisions and inform to be used by our community that can opportunities in Europe, in healthcare preferences

8.00 11.00 BROADGATE SUITE 3 DAY ONE - TUESDAY 7TH FEBRUARY 2017

ROUNDTABLES OR 1-2-1 PARTNERING CEO FORUM Join one of 8 roundtables on a specific strategic theme or 11.30 Therapeutic area and join a 12-person, moderated 11.30

BROADGATE SUITE discussion with practical outcomes. Limited places exist. BISHOPSGATE SUITE

HOW TO GET THE MOST VALUE HOW TO EQUITY CROWDFUND OUT OF YOUR IP HealthEx CEO Forum is a biannual closed door, Chatham House Rule, Isobel Finnie, UK & EU Patent Attorney Daniel Oliver, CEO invite only forum for CEOs, CFOs and Chairmen of listed and soon-to-be listed life science and healthcare companies. EUROPEAN PATENT AND TRADE MARK ATTORNEYS This forum provides peer-to-peer review and open, honest and frank debate between like minded HOW TO ACCESS DEBT FINANCE HOW TO ATTRACT AND RETAIN TALENT executives and a selection of prominent investors. Nooman Haque, Director of Healthcare & John Jakenfelds, Global Practice Life Sciences Leader for Life Sciences and Melanie The forum will provide opportunities West, Consultant for executives to share their successes and debate the opportunities and obstacles that sit between them and their strategic ambitions.

You must be a HEALTHEX Badge Holder to access this forum. PARTNERING IN NEUROSCIENCE AUTOIMMUNE DISEASES: FUTURE R&D The first 1hr 15mins session will Jennifer Laird, Senior Director, Adam Houghton, Senior Director & provide a deep-dive into the results Neuroscience Search & Evaluation Head, Immunology Search & Evaluation of the commissioned Investor survey and report.

Executives will be joined by a number of life science sector institutionals and cross-over funds to discuss the results in more detail, interrogate the data and provide INFECTIOUS DISEASE ADVANCED THERAPIES conclusion notes.

Michel de Baar, Executive Director, Matthew Durdy, CBO Moderator: Business Development, Early Stage S&E, Infectious Disease Europe Terry O’Dwyer, Co-CEO, Biotech and Money

1-2-1 PARTNERING

If the roundtables don’t interest you, get a head start on your 1-2-1 partnering and use this 1hr 15mins session to lock in those all important face-to-face meetings.

If you’ve not pre-secured a table within the partnering room, meet at one of the three ‘Buzz Stops’ on the atrium floor for more informal conversations.

12.45 NETWORKING LUNCH SUPPORTED BY 4 ROUNDTABLES Specific Funding and Finance themed Roundtables 11.30 Max.12 persons per table. Seats are allocated first come, first served via online survey and onsite sign-up sheets.

BROADGATE SUITE If spaces exist on the onsite sign-up sheets, add your name. You must be signed up to attend these sessions.

TABLE 1: TABLE 2: HOW TO GET THE MOST MOST VALUE OUT OF YOUR IP HOW TO EQUITY CROWDFUND

Isobel Finnie, UK and EU Patent Attorney Daniel Oliver, CEO

EUROPEAN PATENT AND TRADE MARK ATTORNEYS

- Creating an IP strategy to fit your business plan and ensuring - Equity Crowdfunding is growing fast - it’s set to overtake VC your IP is due diligence ready investment in the Eurozone by 2020. But how does it really work? - The patentability/patent eligibility of biotech inventions is in flux: navigating this to have an internationally robust patenting - Specialist-led crowdfunding platforms are already used to strategy fund Pharma Series B in the US, and multi-million rounds are already happening in Europe - What you can do about conflicting third party patents - Sector focused crowdfunding is starting to bring real value to Angels and proving to be the perfect complement to highly knowledgeable investors

TABLE 3: TABLE 4: HOW TO ACCESS DEBT FINANCE HOW TO ATTRACT AND RETAIN TALENT

Nooman Haque, Director of Healthcare & Life Sciences John Jakenfelds, Global Practice Leader for Life Sciences and Melaine West, Consultant

Debt finance has become an established way to support life It is estimated that 100+ leadership teams (“Growing the next science companies whilst preserving equity structures and generation of UK Management Talent” BIA, 2016) are required assisting investors in their reserves strategy. This session will over the coming years to build and drive new biotech explore how and when to utilise debt finance in support of your companies towards commercial success. R&D and early development. A session for life science companies that have at least raised a Series A from - What can be done/is being undertaken to actually solve this institutional investors and may still be in R&D/early challenge in the near term? commercial development.

A case-study table discussion led by the host and guided by participants focusing on the following key themes:

- Why is debt finance in life sciences R&D so much more prevalent in Europe and the US, but not in the UK?

- When are investors likely to support a debt facility?

- Learn about the benefits, challenges & structuring techniques of debt finance and when to utilise it for the maximum advantage 12.45 NETWORKING LUNCH SUPPORTED BY 5 ROUNDTABLES Specific Therapeutic area Roundtables 11.30 Max.12 persons per table. Seats are allocated first come, first served via online survey and onsite sign-up sheets.

BROADGATE SUITE If spaces exist on the onsite sign-up sheets, add your name. You must be signed up to attend these sessions.

TABLE 5: TABLE 6: PARTNERING IN NEUROSCIENCE AUTOIMMUNE DISEASES: FUTURE R&D DIRECTIONS

Jennifer Laird, Senior Director, Neuroscience S&E Adam Houghton, Senior Director & Head, Immunology S&E

Neurodegenerative Diseases - Remaining unmet needs in the disease areas of - Novel therapeutic approaches for disease modification in Rheumatology, Dermatology and Gastroenterology neurodegenerative diseases, especially Alzheimer’s disease and Parkinson’s disease - Future therapeutic targets and modalities – what can we - Novel treatments that address the symptoms of leverage from R&D in the field of Immuno-Oncology? neurodegenerative disease including psychosis, cognitive impairment, agitation, mood and sleep - Can future therapies be “personalised” through the development of predictive biomarkers and diagnostics? Biomarkers - Blood-based biomarkers for early detection of amyloid- positive dementia - Wearable technologies and smartphone applications for early detection of Alzheimer’s disease initiation and progression

Pain and Migraine - Novel approaches to treat chronic neuropathic, inflammatory or visceral pain - Migraine prophylaxis

TABLE 7: TABLE 8: INFECTIOUS DISEASE ADVANCED THERAPIES

Michel de Baar, Executive Director, Business Development, Matthew Durdy, Chief Business Officer Early Stage Search & Evaluation, Infectious Disease Europe

Exploring the microbiome for new drugs and targets to provide Ways to reduce perceived risk and increase value ahead of new treatments for patients seeking funding:

- Can we apply conventional research approaches, clinical - Capital cost, control and IP preservation: alternatives design and business models to develop a successful strategies to contract management and “build your own microbiome-biotech? factory”

- How can biotech and big pharma collaborate to accelerate - Cost of goods: planning for and integrating automation and R&D within the microbiome field? other ways to address cost of goods concerns.

- How can we provide evidence of efficacy through a relatively - Product design: product, pricing, service, reimbursement undefined ‘organ’? and preparing for competition.

12.45 NETWORKING LUNCH SUPPORTED BY 6 will allow will allow Managing Director, Managing Director, Managing Director, Managing Director, Corporate Partner and Partner Corporate TALKS AND CASE STUDIES CASE AND TALKS second 2hr session second 1.45 The be to studies and case talks by the and peer-reviewed presented learn to enabling executives group, and successful practice best from approaches. Banking Outlook 1. Investment - BMS Therapeutics 2. PsiOxus Agreement Licensing 3. Nasdaq - US Public Listing and Moderators: Presenters Gil Bar-Nahum, Jefferies Healthcare, Global Gary Green, Equity Capital Head of Global McKenna CMS Cameron Markets, Asaf Homossany, EMEA, Nasdaq

CEO FORUM CEO BISHOPSGATE SUITE -

, ment Partner, Partner, Senior Vice Senior Vice Co-CEO, Co-CEO, of high net Co-Founder Co-Founder Partner, Medicxi Partner, Partner, Partner, sciences reimagined Managing Partner, Managing Partner, environment environment Managing Partner, Managing Partner, The rise of the Vice President, President, Vice Executive Director, Director, Executive Managing Director VP, Venture Investments, Investments, VP, Venture impact invest Family Office in life in life Office Family Managing Director, Fort Fort Managing Director, Managing Director, Merck Merck Managing Director, Corporate venture & venture Corporate EU venture financing EU venture Neil Darkes, Neil Darkes, and Money Biotech Track Host Track Partner, BXR Partners Partner, Chairman & CEO, Privos Chairman & CEO, Privos Adam Kostyál, Adam Kostyál, Deborah Harland, Deborah James Shaw, 1.45 2.25 1.45 3.05 and follow-on investments in the UK investments and follow-on and EU. Moderator: Europe, Services, Listing President, Nasdaq Wezel, van Edward Ventures BioGeneration de Rubertis, Francesco Genghis Lloyd-Harris, Abingworth Papiernik, Antoine Partners Sofinnova Johnston Erwin, Johnston Development Business Corporate & Co. Eli Lilly E Green, Carolyn Worldwide Pfizer Investments, Strategic R&D, ERDI UK, EU and US venture invite We an open host to fund Executives on the continued debate and frank on the capital venture of influence growth for and their appetite sector We invite UK and EU Executives from from UK and EU Executives invite We venture corporate active the most nature the evolving discuss arms to in funding and of their role stage and growth supporting early companies. Moderator: SR-One Jeanne Bolger, JJDC Roel Bulthuis, Ventures Roberto Barzi, Roberto Rock Capital Katai, Bence We invite a selection of leading Fam of leading a selection invite We to executives and advisory Offices ily the turning tide discuss in promising invest willing to worths technology. and medical science life Moderator: Baker Shaw JAG and Partner, Chris Donegan, Associates Capital Invention Dan Farrell, (MFO) Office Multi-Family Capital, BROADGATE 2 EARLY / GROWTH-STAGE / EARLY - Head of Managing

SVP, Head of Life Head of Life Managing Director, Managing Director, Senior Director, Senior Director, Accelerating Accelerating collaborations Co-Founder and Co-Founder Strengthening UK Strengthening role in early stage stage in early role Executive Director, Director, Executive Pharma’s evolving evolving Pharma’s for VC and pharma VC for CIO, Karolinska CIO, Karolinska Managing Director, Tech Tech Managing Director, and EU seed funding promising programs programs promising Managing Investment Managing Investment Head, Tech Transfer, Life Life Transfer, Head, Tech General Manager, KU Manager, General UK and EU Patent UK and EU Patent Josh Dance, Josh Dance, and Money Biotech Savvas Neophytou, Neophytou, Savvas AFTERNOON REFRESHMENTS AFTERNOON Iain Thomas, Executive Director, UCL UCL Director, Executive Adrian Dawkes, Adrian Dawkes, Director of External of External Director

1.45 2.25 1.45 3.05 Sciences, Oxford University Innovation University Oxford Sciences, Isobel Finnie, Haseltine Lake Attorney, Business Business Dun, van Paul and Development Research Leuven Adam Stoten, Sciences, Cambridge Enterprise Cambridge Enterprise Sciences, Hickson, Tony Innovations Imperial Transfer, Anne Lane, effecting to support early stage. early support to effecting Moderator: Heads to discuss the innovative the innovative discuss Heads to by the being taken approaches they roles and the offices various are they and the outcomes play, We invite UK and EU Tech Transfer Transfer and EU Tech UK invite We Søren Møller, Møller, Søren Seeds Novo Director, Viktor Drvota, Drvota, Viktor Development Michael Brandkamp, Gründerfonds High-Tech Moderator: Moderator: Deepbridge Capital Sciences, Life Takke, Christina V-Bio Ventures Managing Director, dynamic that presently exists across across exists dynamic that presently it will take what and debate Europe market. a EU seed capital create to We invite representation from from representation invite We UK and a number of prominent the discuss to seed funds European Business Development, Early Stage Stage Early Development, Business Disease Infectious & Evaluation, Search MSD Europe, Eli Lilly & Co. Eli Lilly Wengel, Nathalie ter R&D Worldwide R&D Innovation, External Michel de Baar, Moderator: Moderator: Ltd PharmaVentures Director, Tim Luker, R&D, External Global for Innovation dynamic and role that pharma play dynamic and role collabora and finance stage in early the continent. tions across We invite a selection of Europe’s of Europe’s a selection invite We Heads pharma innovation leading the evolving and debate discuss to

3.45 SEED / EARLY-STAGE / SEED BROADGATE 1 7 CEO FORUM BROADGATE 1 BISHOPSGATE SUITE BROADGATE 2 Spotlight on 4.15 Medicines Discovery 4.15 4.15 Catapult The Medicines Discovery Catapult CEOs from the UK and Europe’s has been established as a private most progressive drug discovery, sector, industry focused, development and tool companies The third 1hr 45mins session will be independent organisation to develop take to the podium to pitch their split into 3 sections. new approaches for the discovery company and research to qualifed and early development of new medi- investors and pharma BD&L heads. The first45mins will allow intimate, cines helping to transform ideas into 6-8 person roundtable discussions commercial products and services. 7 companies will present for 15mins between the group of executives. inc. Q&A. The MDC will develop and ROUNDTABLE TOPICS validate new ways of discovering Peter Pack, CEO, Crescendo new medicines and supporting the Biologics The themes will be crowdsourced key UK strength in pharmaceutical, from the Executives themselves in biotechnology and contract research the previous session. Executives will organisations. then be allocated their own small roundtable group in which to debate Chris Molloy, CEO, Medicines and discuss their issues. Discovery Catapult Alan Walker, CEO, Ryboquin GROUP FEEDBACK 4.35 Attracting China’s Following the discussion, 30mins start-up and growth will be allocated to allow all groups funding to feed back their individual We invite a panel of Chinese in- learnings at the end of the session. vestment Executives and industry Manuel Llobet, CEO, Allergy stakeholders to discuss why China’s Therapeutics OUTCOMES start-up funding is heading to the UK and what we can expect to see The final30mins will be used to from what many are saying is a agree upon tangible outcomes and golden age of UK-China cooperation. deliverables to progress the forum for the next CEO Forum in Moderator: John Hodgson, Data Editor, September. Pharma, SCRIP Intelligence Aram Mangasarian, CEO, Noxxon Jiansheng Du, Life Science Specialist, Pharma Department for International Trade Moderator: Simon Haworth, Founder and CEO, Dynasty Bio and Sino-UK Fund Chris Moore, EMEIA Life Sciences Rob Scott, Director, China BlueSky Lead Partner, EY Partners and Investment Director (China), Bio Capital Impact Fund Neil Miller, CEO, Auspherix

Crossover and 5.15 alternative investment groups We invite prominent vc / crossover funds to discuss their strategies and Scott Robinson, Founder and CSO, appetites towards VIPEs and ‘top-up’ MicroQuin financing to both IPO-ready and IPO’d companies. Plus discuss the benefits their approach brings to the corporates themselves.

Moderator: James Shaw, Co-Founder and Partner, JAG Shaw Baker Luc Dochez, CEO, Tusk Therapeutics Chau Khuong, Private Equity Partner, Orbimed Chandra Leo, Partner and Investment Advisor, HBM Partners

NETWORKING DRINKS RECEPTION 6.00 Investors who have registered for the Investor Dinner at Andaz London Hotel, you will be directed from the conference venue at 7.15pm.

8 Hong Hu, Research Advisor, Lilly Research Laboratories

It begins with a promise to discover medicines that make life better.

Since 1876, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

The new national, independent centre of expertise for the discovery and proof of new medicines

• Building partnerships • Removing bottlenecks • De-risking investments • Finding Fast to Patient Solutions

We will support the UK’s strong biopharma sector by creating innovative new collaborations with medical research charities, technologists, venture capital funders, regulators and translational academics to bring more medicines into clinical trials.

We are here to help the UK remain a world-leader in drug discovery.

If you want to find out more about our work visit md.catapult.org.uk or contact us on: [email protected] You can also follow us at: @MedDiscCat

A4_BioTechMoney_Ad_02.indd 1 13/01/2017 12:04 DAY TWO - WEDNESDAY 8TH FEBRUARY 2017 8.30 REGISTRATION AND BREAKFAST BROADGATE 2 WELCOME BROADGATE 1 WELCOME 9.00 Neil Darkes, Co-CEO, Biotech and Money 9.00 Matt Pullan, SVP, BD, Biotech and Money ‘ANATOMY OF A...’ MEDTECH COMMERCIAL 9.10 PRIVATE FINANCE RAISE 9.10 LEADERS KEYNOTE PANEL We invite Executives from UK and EU life science companies We invite a mix of EU and US commercial leaders from large that have recently concluded successful private finance and mid-sized global corporates in medtech to discuss how raises to share their war stories, KSFs and opinions on they see the medtech industry evolving, their investment current venture fund appetite. role in this evolution, what is attracting their attention and how are investments being structured. Plus, what we can expect from the companies themselves in the coming year. Moderator: Brian Lovatt, CEO, Vision Healthcare Consultancy Zeev Zehavi, VP, Venture Investments, Medical Devices, JJDC Moderator: Joe Pillman, Strategic Business Consultant, JAG Shaw David Neustaedter, VP, Venture Capital, Medtronic Baker Jonathan Goldstein, Director, Corporate Research and Ventures, Nicholas Benedict, CEO, Allecra Therapeutics Boston Scientific Ventures Niall Martin, CEO, Artios Pharma Andreas Wuepper, Director Investments Europe, Fresenius Medical Robert Tansley, Investment Director, Healthcare, Cambridge Care Ventures Innovation Capital Assaf Barnea, CEO, Sanara Ventures Luc Dochez, CEO, Tusk Therapeutics

‘ANATOMY OF AN...’ 9.50 INNOVATIVE DEAL STRUCTURE We invite Executives from UK and EU life science companies that have recently conducted successful deals to share their war stories, KSFs and opinions on the deal making environment. MEDTECH INTENT: Plus, what we can expect from the companies themselves in KEYNOTE INVESTOR PANEL the coming year. 10.00 We invite a mix of active UK, EU and US venture capital and Moderator: Philip Broke, Partner, White & Case funds in medtech to discuss the range of sources of Thomas Taapken, CFO, Medigene funding and investment open to medtech and medical Peter Pack, CEO, Crescendo Biologics device companies, and what they are looking for in an Cord Dohrman, CSO, Evotec investable business Ray Barlow, Executive Director, Corporate Development, Amgen Phil L’Huillier, Director of Business Management, Cancer Research Moderator: Madeleine Armstrong, Reporter, EP Vantage Technology Daniel O’Mahony, Partner, Seroba Life Sciences Peter DInes, Investment Director, Mercia Technologies Christoph Ruedig, Partner, Albion Ventures Josep Sanfeliu, Co-Founder and Managing Partner, Ysios Capital Partners Rainer Strohmenger, General Partner, Wellington Partners ‘ANATOMY OF AN...’ Anne Portwich, Partner, LSP 10.30 EQUITY CROWDFUND We invite a leading Crowdfunding platform and a corporate that has been successful in raising and closing financing rounds to share their war stories, KSFs and best practice to securing the desired outcome.

Goncalo de Vasconcelos, Co-Founder and CEO, SyndicateRoom

10.50 MORNING REFRESHMENTS, 1-2-1 PARTNERING AND NETWORKING 11 8.30 REGISTRATION AND BREAKFAST BISHPOPGATE 2 BISHOPSGATE 1 WELCOME WELCOME 9.00 Terry O’Dwyer, Co-CEO, Biotech and Money 9.10 Josh Dance, SVP, Biotech and Money 9.101 9.10 CEOs from the UK and Europe’s most progressive drug CEOs from the UK and Europe’s most progressive medtech discovery, development and tool companies take to the and device companies take to the podium to pitch their podium to pitch their company and research to qualifed company and technology to qualifed investors and pharma investors and pharma BD&L heads. BD&L heads.

Companies will present for 15mins inc. Q&A. Companies will present for 15 mins inc. Q&A.

Gregg Sando, CEO, Cell Medica Peter Crosby, CEO, Mainstay Medical

Thomas Taapken, CFO, Medigene Martin Frost, CEO, Cambridge Medical Robotics

Ted Fjällman, CEO, Prokarium Peter Hoyer, CCO, Quanta Dialysis Technologies

Tim Dyer, CEO, Addex Therapeutics Kam Pooni, CEO, Glyconics

Robert Scoffin, CEO, Cresset Federico Bürsgens, Managing Director, GNA Biosolutions

Rainer Lichtenberger, CEO, Atriva Therapeutics Andy Anderson, CEO, Oxford Impedance Diagnostics

10.40 MORNING REFRESHMENTS, 1-2-1 PARTNERING AND NETWORKING 12 Executive Chairman, Executive Chairman, Glycostem Co-Founder & CEO, Co-Founder CEO, Zilico Ltd. CEO, Zilico CEO, Fimmic Oy CEO, Curasight CEO, Censo Biotechnologies CEO, Calcivis President of the Board, of the Board, President CEO, Xbrane CEO, Desentum CEO, TRN CEO, Anima Biotech CEO, Anima CEO, Momentum Bioscience CEO, Jupiter Diagnostics CEO, Jupiter CEO, SurgaColl Technologies CEO, SurgaColl 11.20 11.20 Sameer Kothari, Getley, Christopher AgPlus Diagnostics Kaisa Helminen, Bill Mullen, Bill Mullen, Adam Christie, Pradella, Lorenzo Ortho Greenbone Chris Ball, Bill Allan, Aidan Courtney, Aidan Courtney, Charles Woler, Woler, Charles NovellusDx Slonim, Yochi Mattila, Pekka Martin Amark, Jordansen, Troels Andy McElroy, Persson, Morten

BISHOPSGATE 1 BISHOPSGATE 2

Medtech Medtech Corporate Corporate Editor in Chief, Editor Investment Director, Director, Investment Senior Managing Chairman, PBD Biotech Chairman, PBD Biotech Chairman, 11 Health & Investment Director, Director, Investment Life Science Partner Science Life CEO, Avita Medical Medical CEO, Avita Chairman, ESP ‘Anatomy of a...’ ‘Anatomy healthy strong, valuation CEO, Mainstay Medical Medical CEO, Mainstay ‘Anatomy of...’ ‘Anatomy medtech commercialisation ‘Anatomy of a...’ of ‘Anatomy private Medtech raise finance CEO, Cambridge Medical CEO, Cambridge Medical CCO, Quanta Dialysis Dialysis CCO, Quanta CEO, Veryan Medical CEO, Veryan Gary Green, Gary Green, Tina Tan, Tina Tan,

Elizabeth Cairns,

12.40 12.00 11.20 Director, OrbiMed Advisors OrbiMed Advisors Director, companies that continue to post post to that continue companies market healthy growth, strong record and a solid track valuations their thoughts on why the share to be the to is likely sector medtech and AIM private to attractive most 12 months. the next over investors Moderator: Equity Capital and Head of Global Partner McKenna CMS Cameron Markets, Spicer, Charles Medical and Creo Technologies Chas Taylor, Darvish, Nissim We invite Executives from medtech medtech from Executives invite We Peter Crosby, Crosby, Peter Berwyn Clarke, Alan Edwards, and Asep Healthcare Technology, Tek Stent Director, Non-Exec We invite Executives from medtech medtech from Executives invite We successfully that have companies companies built and commercialised KSFs and their war stories, share to should companies the strategies growth. for in the quest pursue Moderator: Insight Medtech Hoyer, Peter Technologies Moderator: Moderator: EP Vantage Reporter, Schmitz, Alexander Vision Endeavour Vijay Barathan, Catapult Fund, Sciences GM&C Life Ventures David Holbrook, and Venture Cambridge Enterprise Ventures MTI Partner, Martin Frost, Robotics Adam Kelliher, We invite Executives from medtech medtech from Executives invite We that companies health and digital private successful concluded have war their to share raises finance on KSFs and opinions stories, appetite. fund venture current BROADGATE 1 Director of Director Managing Editor, Editor, (TBC) Managing Director, Managing Director, CEO, TiGenix Group CEO, WideCells Group CEO, Ablynx CEO, Ablynx ‘Anatomy of an...’ ‘Anatomy Initial Public Offering CEO, Heptares CEO, Heptares ‘Anatomy of a...’ of a...’ ‘Anatomy debt finance ‘Anatomy of an...’ of ‘Anatomy asset / acquisition acquirer CEO, Cell Medica CEO, Cell Medica CEO, FIT Biotech Operating Partner, Partner, Operating Lisa Urquhart, Lisa Urquhart, Nooman Haque, CEO, Chronos Therapeutics Therapeutics CEO, Chronos Adrian Dawkes, Adrian Dawkes,

12.40 12.00 11.20 Group plc Group Bravo, Eduardo Asaf Homossany, EMEA, Nasdaq Moderator: Moderator: EP Vantage Joao Andrade, Plus, what we can expect from the from expect can Plus, what we in the coming themselves companies year. concluded successful public listings public listings successful concluded and KSFs their war stories, share to public market opinions on current appetite. investor We invite Executives from UK and from Executives invite We that have companies science EU life Moderator: Sciences & Life Healthcare Edwin Moses, James Kuo, Plus, what we can expect from the from expect can Plus, what we in the coming themselves companies year. could pave the way for other the way for pave could alternative for looking companies finance. benefitted from issuing convertible convertible issuing from benefitted their approaches, share bonds to their experiences KSFs and how We invite Executives from UK and from Executives invite We that have companies science EU life Rob de Ree, Ventures BioGeneration Director, PharmaVentures Ltd PharmaVentures Director, Sando, Gregg Huw Jones, Weir, Malcolm companies themselves in the coming in the coming themselves companies year. Moderator: acquisition route. acquisition route. the from expect can Plus, what we EU life science companies that have that have companies science EU life to acquisitions completed recently KSFs and their war stories, share the on heading down rationale We invite Executives from UK and from Executives invite We BROADGATE 2 13 1.20 NETWORKING LUNCH AND 1-2-1 PARTNERING BISHOPSGATE 1 BROADGATE 1 BROADGATE 2 ‘Anatomy of a...: ‘Anatomy of a...’ 2.20 M&A and exit 2.20 medtech IPO and 2.20 public raises We invite prominent Executives from We invite Executives from medtech Claus Marquordt, Managing Director, UK and EU biotech, pharma and companies that have concluded RD-Support Investment Banks to outline their successful public and private finance thoughts and views on M&A, trade raises to share their war stories, sale appetite and market forces KSFs and what it takes to get an IPO affecting this dynamic in 2017. away in todays climate. David Tuch, CEO, Lightpoint Medical

Moderator: John Hodgson, Data Editor, Moderator: Philip Broke, Partner, White Pharma, SCRIP Intelligence & Case Tim Edwards, Former Chairman, Atopix Achim Plum, CCO, Curetis Therapeutics Sophie Baratte, CEO, Cellnovo James Garvin, CEO, CytoBioscience Lucas de Breed, Director, INKEF Capital Simon Hubbert, CEO, Lombard Medical Alex Leech, CEO, Creabilis

Healthcare outlook; Medtech outlook; BISHOPSGATE 2 3.00 what’s hot and what’s 3.00 what’s hot and 2.20 not what’s not We invite leading life science and We invite leading Medtech Analysts Ian Quirk, CEO, Active Needle Technology healthcare Analysts to share their to share their views on what are the views on what are the trends driving trends driving investment and wider investment and wider opportunities, opportunities, what device areas are what therapeutic areas are attracting the most attention and Edward Bruce-White, CEO, Combat attracting the most attention and what predictions are Analysts Medical what predictions are Analysts making for the next 12 months. making for the next 12 months. Moderator: Tina Tan, Editor in Chief, Moderator: Sam Fazeli, Head of Medtech Insight European Research, Pharamceuticals Michael King, Medical Technology Sorin Popa, CEO, Stent-Tek Analyst, Bloomberg Intelligence Research Analyst, Rx Securities Paul Cuddon, Director, Healthcare Equity Mick Cooper, Healthcare and Life Research, Numis Securities Sciences Analyst, Trinity Delta Julie Simmonds, Director, Equity Research, Panmure Gordon Max Herrmann, Managing Director, Stifel Amy Walker, Partner, Healthcare Equity Research Analyst, Peel Hunt

3.40 AFTERNOON REFRESHMENTS FOLLOWED BY CLOSE OF CONGRESS 14 YOUR ONSITE GUIDE TO THE 40+ DRUG DISCOVERY & DEVELOPMENT, MEDTECH AND MEDICAL DEVICE INV€$TABLE SHOWCASES

15 Presenter: Ian Quirk, CEO Presenter: Tim Dyer, CEO Presenter: Christopher Getley, Track: Medtech Inv€$table Track: Biotech Inv€$table Executive Chairman Room: Bishopsgate 2 Room: Bishopsgate 1 Track: Medtech Inv€$table Time: 2.20pm, Wednesday 8th Time: 9.55am, Wednesday 8th Room: Bishopsgate 2 Time: 12.50pm, Wednesday 8th Market/Technology: Market/Disease Indication: Address the universal problem Focused on the development Market/Technology: of needle placement errors of novel, orally available, small A diagnostic platform that will in ultrasound-guided needle molecule allosteric modulators for deliver against the demanding interventional procedures. neurological disorders market requirements of a true quantitative PoC, across a wide range of clinical applications. Ownership: Private Ownership: Public, SWX: ADXN Ownership: Private URL: www.activeneedle.com URL: www.addextherapeutics.com URL: www.agplusdiagnostics.com

Presenter: Manuel Llobet, CEO Presenter: Yochi Slonim, CEO Presenter: Rainer Lichtenberger, Track: Biotech Inv€$table Track: Biotech Inv€$table CEO Room: Broadgate 1 Room: Bishopsgate 1 Track: Biotech Inv€$table Time: 4.45pm, Tuesday 7th Time: 11.35am, Wednesday 8th Room: Bishopsgate 1 Market/Disease Indication: Market/Disease Indication: Time: 10.25am, Wednesday 8th Prevention, diagnosis and Pioneering Translation Control treatment of allergic conditions Therapeutics, a new class of drugs Market/Disease Indication: with a special focus on allergy that control protein translation. Repurposing existing so-called vaccination (also known as specific Our novel drug discovery platform MEK-inhibitors. First-in-class immunotherapy. enables a new therapeutic strategy inhibitors against seasonal and to approach hard / undruggable pandemic influenza. protein targets. Ownership: Public, LON: AGY Ownership: Private Ownership: Private URL: www.allergytherapeutics.com URL: www.animabiotech.com URL: www.atriva-therapeutics.com

Presenter: Neil Miller, CSO Presenter: Adam Christie, CEO Presenter: Martin Frost, CEO Track: Biotech Inv€$table Track: Medtech Inv€$table Track: Medtech Inv€$table Room: Broadgate 1 Room: Bishopsgate 2 Room: Bishopsgate 2 Time: 5.15pm, Tuesday 7th Time: 11.35am, Wednesday 8th Time: 9.25am, Wednesday 8th Market/Disease Indication: Anti-infectives company that Market/Technology: Market/Technology: developing a novel class of The CALCIVIS dental imaging Cambridge Medical Robotics is a organogold-based antibiotics, system uniquely allows the live fast growing technology company designed to help address the visualisation of active tooth developing a break-through worldwide healthcare crisis of demineralisation, enabling a new platform solution for robotic AMR. standard of preventive care in keyhole surgery. dentistry. Ownership: Private Ownership: Private Ownership: Private URL: www.auspherix.com URL: www.calcivis.com URL: www.cmedrobotics.com 16 Presenter: Gregg Sando, CEO Presenter: Aidan Courtney, CEO Presenter: Edward Bruce-White,CEO Track: Biotech Inv€$table Track: Biotech Inv€$table Track: Medtech Inv€$table Room: Bishopsgate 1 Room: Bishopsgate 1 Room: Bishopsgate 2 Time: 9.10am, Wednesday 8th Time: 1.05pm, Wednesday 8th Time: 2.35pm, Wednesday 8th Market/Disease Indication: Market/Technology: Cell Medica develops, Market/Disease Indication: Multi-patented, hyperthermic, manufactures and markets Censo Biotechnologies Ltd is a cancer treatment delivery systems personalized cellular stem cell technology company for the bladder and various organs immunotherapeutics for cancer providing human cells and within the peritoneal cavity. and infectious diseases. contract research services for drug Enhancing delivery & increasing discovery, toxicity testing and cell efficacy of existing & new drugs in banking. cancers. Ownership: Private Ownership: Private Ownership: Private URL: www.cellmedica.co.uk URL: www.censobio.com URL: www.hivec.co.uk

Presenter: Peter Pack, CEO Presenter: Robert Scoffin, CEO Presenter: Morten Persson, CEO Track: Biotech Inv€$table Track: Biotech Inv€$table Track: Biotech Inv€$table Room: Broadgate 1 Room: Bishopsgate 1 Room: Bishopsgate 1 Time: 4.15pm, Tuesday 7th Time: 10.10am, Wednesday 8th Time: 12.50pm, Wednesday 8th Market/Disease Indication: Crescendo Biologics is a Market/Disease Indication: Market/Disease Indication: biopharmaceutical company Cresset provides outstanding Curasight is a pioneer in the field discovering and developing contract research services for of exploiting a novel PET imaging differentiated, multifunctional molecule discovery, optimisation target - the urokinase-type Humabody® therapeutics in and supply. plasminogen activator receptor Oncology. (uPAR) - for improved breast cancer diagnose. Ownership: Private Ownership: Private Ownership: Private URL: www.crescendobiologics.com URL: www.cresset-group.com URL: www.curasight.com

Presenter: James Garvin, CEO Presenter: Pekka Mattila, CEO Presenter: Kaisa Helminen, CEO Track: Medtech Inv€$table Track: Biotech Inv€$table Track: Medtech Inv€$table Room: Bishopsgate 1 Room: Bishopsgate 1 Room: Bishopsgate 2 Time: 2.50pm, Wednesday 8th Time: 11.50am, Wednesday 8th Time: 1.05pm, Wednesday 8th Market/Technology: Market/Technology: Bioscience, nanoscience microchip Market/Disease Indication: Using Deep Learning AI and development, algorithms and A research-oriented cloud computing, Fimmic’s engineering to develop and biopharmaceutical company WebMicroscope Software brings manufacture instrumentation that specialised in developing novel fast and accurate diagnostics supports ion channel research and types of allergen immunotherapy support to medical microscopy, new approaches to disease analysis products. removing slow, manual and and individualised treatment inconsistent workflow. modalities. Ownership: Private Ownership: Private Ownership: Private URL: www.desentum.fi URL: www.webmicroscope.com URL: www.cytocentrics.com 17 Presenter: Kam Pooni, CEO Presenter: Troels Jordansen, Presenter: Federico Bürsgens, Track: Medtech Inv€$table Chairman Managing Director Room: Bishopsgate 2 Track: Biotech Inv€$table Track: Medtech Inv€$table Time: 9.55am, Wednesday 8th Room: Bishopsgate 1 Room: Bishopsgate 2 Time: 12.20pm, Wednesday 8th Time: 10.10am, Wednesday 8th Market/Technology: Market/Disease Indication: Solutions to the definitive An innovator in allogeneic cellular Market/Technology: diagnosis of COPD and the early immunotherapy using Natural Instruments, OEM modules, and identification of exacerbation. A Killer (NK) cells - oNKord® assays for ultra-fast, molecular valuable tool for the design and - or antigen presenting cells pathogen detection using our implementation of novel COPD - sDCord® - for treatment of breakthrough technology: Laser therapeutic interventions. leukemia, lymphoma,solid tumors. PCR. Ownership: Private Ownership: Private Ownership: Private URL: www.glyconics.com URL: www.glycostem.com URL: www.gna-bio.com

Presenter: Lorenzo Pradella, CEO Presenter: Chris Ball, CEO Presenter: David Tuch, CEO Track: Medtech Inv€$table Track: Medtech Inv€$table Track: Medtech Inv€$table Room: Bishopsgate 2 Room: Bishopsgate 2 Room: Bishopsgate 1 Time: 11.50am, Wednesday 8th Time: 12.05pm, Wednesday 8th Time: 2.35pm, Wednesday 8th Market/Technology: Market/Technology: Market/Technology: The company’s molecular imaging Developing a highly innovative, Unlike traditional blood testing technology, based on Cerenkov bone regenerating, load-bearing solutions, our technology offers a Luminescence Imaging, has the implants to treat severe fractures more accessible and faster way to potential to detect cancer in real- and conditions such as trauma and get reliable blood results. time during surgery, providing tumours that result in extensive more accurate cancer treatment bone loss. while sparing healthy tissue. Ownership: Private Ownership: Private Ownership: Private URL: www.greenbone.it URL: www.jupiterdiagnostics.com URL: www.lightpointmedical.com

Presenter: Peter Crosby, CEO Presenter: Thomas Taapken, CFO Presenter: Scott Robinson, CEO Track: Medtech Inv€$table Track: Biotech Inv€$table Track: Biotech Inv€$table Room: Bishopsgate 2 Room: Bishopsgate 1 Room: Broadgate 1 Time: 9.10am, Wednesday 8th Time: 9.25am, Wednesday 8th Time: 5.30pm, Tuesday 7th Market/Technology: Market/Disease Indication: Market/Disease Indication: A European medical device The company is developing highly MicroQuin is a biotechnology, R&D company focused on bringing to innovative, complementary based company. We currently market an innovative implantable treatment platforms to target focus on developing therapeutics neurostimulation system, ReActiv8, various types and stages of cancer to address a range of oncological for people with disabling Chronic with candidates in clinical and pre- disease. Low Back Pain. clinical development. Ownership: Public, MSTY.IE and MSTY.PA Ownership: Public, ETR: MDG1 Ownership: Private URL: www.mainstay-medical.com URL: www.medigene.com URL: www.microquin.com 18 Presenter: Bill Mullen, CEO Presenter: Charles Woler, Presenter: Aram Mangasarian, Track: Medtech Inv€$table President of the Board CEO Room: Bishopsgate 2 Track: Biotech Inv€$table Track: Biotech Inv€$table Time: 11.20am, Wednesday 8th Room: Bishopsgate 1 Room: Broadgate 1 Time: 11.20am, Wednesday 8th Time: 5.00pm, Tuesday 7th Market/Technology: Market/Disease Indication: Market/Disease Indication: A range of innovative diagnostic NovellusDx provides Core focus is on cancer products to help combat antibiotic comprehensive, fully-automated, treatment. NOXXON is using its resistance and sepsis by providing functional gene profiling of proprietary class of drugs called early detection of the presence and individual patient tumors including Spiegelmers* to target the tumor absence of bloodstream infections. charting the full landscape of microenvironment, a new frontier known and unknown mutations. in cancer treatment. Ownership: Private Ownership: Private Ownership: Public, EPA: ALNOX URL: www.momentumbio.co.uk URL: www.novellusdx.com URL: www.noxxon.com

Presenter: Andy Anderson, CEO Presenter: Ted Fjällman, CEO Presenter: John Milad, CEO Track: Medtech Inv€$table Track: Biotech Inv€$table Track: Medtech Inv€$table Room: Bishopsgate 2 Room: Bishopsgate 1 Room: Bishopsgate 2 Time: 10.25am, Wednesday 8th Time: 9.40am, Wednesday 8th Time: 9.40am, Wednesday 8th

Market/Technology: Market/Disease Indication: Market/Technology: Researches, designs and will Prokarium develops oral vaccines Quanta, a pioneering medical market diagnostic tests for the against C.diff, exacerbations of devices company, has developed measurement of clinical bio COPD/asthma, Chlamydia, and advanced haemodialysis systems markers that reduce healthcare under a UK government contract a for use in the home and clinic. costs and improve patient plague vaccine. outcomes. Ownership: Private Ownership: Private Ownership: Private URL: www.oxfordimpedence.com URL: www.prokarium.com URL: www.quantdt.com

Presenter: Claus Marquordt, MD Presenter: Alan Walker, CEO Presenter: Sorin Popa, CEO Track: Medtech Inv€$table Track: Biotech Inv€$table Track: Medtech Inv€$table Room: Bishopsgate 1 Room: Broadgate 1 Room: Bishopsgate 2 Time: 2.20pm, Wednesday 8th Time: 4.30pm, Tuesday 7th Time: 2.50pm, Wednesday 8th Market/Disease Indication: Market/Technology: We use our expertise to turn Market/Technology: Global supplier of bespoke lab-on- under-developed intellectual Stent Tek is developing a novel a-chip development services and property ideas into viable catheter based system that owner of world’s only direct, fast, commercial realities. Focused provides a better way for patients reliable and cheap graphene layer on commercialising patented to receive haemodialysis (HD) for manufacturing process on any technologies in the area of human kidney failure. surface. cancer medicine. Ownership: Private Ownership: Private Ownership: Private URL: www.rd-support.eu URL: www.ryboquin.co.uk URL: www.stent-tek.com 19 Presenter: Bill Allan, CEO Presenter: Andy McElroy, CEO Presenter: Luc Dochez, CEO Track: Medtech Inv€$table Track: Biotech Inv€$table Track: Biotech Inv€$table Room: Bishopsgate 2 Room: Bishopsgate 1 Room: Broadgate 1 Time: 12.20pm, Wednesday 8th Time: 12.35pm, Tuesday 7th Time: 5.45pm, Tuesday 7th Market/Disease Indication: Market/Disease Indication: Market/Technology: EmstoPA, a humanised antibody Tusk Therapeutics is harnessing A medical devices company, fragment for treatment of bleeding the power of the innate immune develops novel tissue regeneration complications in patients who system to fight cancer through products for the surgical treatment have received the clot buster tPA the development of novel immune of disease of bone, cartilage, and (Activase® , Alteplase). tPA is used modulating therapeutics. other human tissue. in conditions caused by blood clots; strokes and pulmonary embolism. Ownership: Private Ownership: Private Ownership: Private URL: www.surgacoll.com URL: www.trn.net URL: www.tusktherapeutics.com

Presenter: Martin Amark, CEO Presenter: Sameer Kothari, CEO Track: Biotech Inv€$table Track: Medtech Inv€$table Room: Bishopsgate 1 Room: Bishopsgate 2 Time: 12.05pm, Wednesday 8th Time: 12.35pm, Wednesday 8th MarketTechnology: Market/Disease Indication: Zilico’s first product, ZedScan, Xbrane is a biopharmaceutical is already making significant company specialized in high impact within the cervical cancer demand biosimilars and long diagnostic pathway. Zilico is acting injectables. also developing other real-time diagnostic devices for oral, anal & oesophageal cancers. Ownership: Public, NASDAQ Ownership: Private URL: www.xbrane.com URL: www.zilico.co.uk

GET INVOLVED AND SHOWCASE YOUR COMPANY AT A FUTURE EVENT

Our mission at Biotech and Money / Medtech and Money is to connect innovative corporates with the right capital.

Inv€$table Showcases are one of the most effective ways that we can help you promote your company or portfolio company to a global audience.

If you’d like to be considered for an Inv€$table Showcase at either the 2nd Inv€Stival Showcase on the 15th November 2017 or at the 4th Biotech and Money / Medtech and Money London Conference on the 6th & 7th February 2018 then send us an email.

Contact Josh Dance at [email protected] to reserve your 15mins showcase.

Showcases at both Inv€$tival Showcase 2016 and Biotech and Money / Medtech and Money London 2017 were sell outs, so don’t leave your enquiry too late.

20 ATTENDING COMPANIES (525+ ATTENDEES, 370+ COMPANIES) 4BIO Capital Partners CytoBioscience Kreos Capital PharmaVentures Abbvie Danish Growth Capital II KU Leuven R&D Pharmedartis Abingworth Deep Knowledge Life Sciences Kurma Partners Pragma Therapeutics Ablynx NV Deep Knowledge Ventures L1 Capital / Europe Offering Precious Cells Abzena Deepbridge Capital Lakeside Healthcare Privos Capital Active Needle Technology Deepbridge Syndicate Lakeside Plus Prokarium Addex Therapeutics Deltex Medical Group LBA Ventures ProteoDesign AdRem Capital Department for International Trade Legal & General Investment Management Proteome Sciences Advent Life Sciences Desentum Oy Levrett PLC PsiOxus Therapeutics Advisory London Dievini Hopp BioTech holding GmbH & Co Life Sciences Hub Wales PsyOmics Aetas Global Markets Discuva Life Sciences Partners Qbtech Aglaris Ltd. Domainex / Canbex Therapeutics LifeSci Advisors Quanta Dialysis Technologies AgPlus Diagnostics Drais Pharmaceuticals Lightpoint Medical QuantuMDx Group Alacrita Drug Discovery Today Lombard Medical RBV Capital Albion Technology & General VCT e-consultancy Longevity Venture Partners RD-Support Albion Ventures Edesa Biotech M-V Arterica Redline Captal Allecra Therapeutics EGB Advisors PR Mainstay Medical Limited ReNeuron Allergy Therapeutics Eli Lilly & Co. Majid Al Futtaim Trust ReViral Amadeus Capital Partners Endeavour Vision Mann Bioinvest Rex Bionics Amgen Enso Ventures Marketing Birmingham RMI Partners Anima Biotech EP Vantage Marks & Clerk Rosetta Capital Apposite Capital Epidarex Maven Capital Partners Rothschild & Co. Aptamer Group EQS Medicine Discovery Catapult Roundcape Aptamer Solutions Ergomed Medicon SD Ltd Ruffena Capital Arix Bioscience Esperante Medicxi RX Securities Arthurian Life Sciences EURASANTE Medigene Ryan-Kay Artios Pharma Evernow Publishing Ltd MedInnovation Ryboquin Artios Therapeutics Evotec MedTech Imperial Ryboquin Company ASep healthcare Exonate Medtech Insight Sanara Ventures Astex Pharmaceuticals EY Medtronic Saniona Atelix F-Prime Capital Memcor Scancell Holdings Atopix Therapeutics Family Office Mercia Fund Managemnet SCIAD Atriva Therapeutics Fimmic Oy Mercia technologies Scottish Equity Partners Auspherix Financial Times Merck SCRIP Avita Medical FIT Biotech Merck Ventures SCRIP Intelligence Bactevo Fladgate Meyer & Co Sensiia Barclays Forbion Capital Partners Microbiotix Sentinel Oncology Beaufort Securities Forrest Innovations MicroQuin Seroba Life Sciences Belsize Asset Management Fort Rock Capital Midatech Pharma Silicon Valley Bank Bergen Asset Management FreeMind Group Miotech Medpartners Sino-UK Fund BioCatalyst Capital Partners Fresenius Medical Care Ventures MIRABAUD Securities Sixth Element Capital BioGeneration Ventures Galecto Biotech Mitotech SJB Technical Recruitment Bionow Gill Jennings & Every Momentum Bioscience Sofinnova Partners BioPharm Insight - Mergermarket Group Glyconics MP.com Solvotrin Therapeutics BioSeed Capital Glycostem MRC Technology SR-One Biotech and Money GNA Biosolutions MSD Stent-Tek Biotech Growth Trust GR Capital Multipharma SA Stevenage Bioscience Catalyst Bloomberg GreenBone Ortho MVM Life Science Partners Stifel Boston Scientific Ventures GTL Investments N+1 Singer Sunergos Innovations Bracknor Investment Group Hadean Ventures Nanobiotix Sunstone Capital Brewin Dolphin Harbert European Growth Capital Narec Capital Ltd SurgaColl Technologies Bristows Haseltine Lake Nasdaq SV Life Sciences British Expats in Life Sciences HBM Partners Nature Biotechnology Syncona British Pharmacological Society HealthCap NeoMed Syndicate Room BROTHERS & Partners Europe HealthCare Royalty Partners NetScientific Takeda Ventures, Inc. (TVI) BWL Investments Heptares Therapeutics New Hope Investments Talentmark BXR Partners Hermes Pacific Capital New Mosaic Ltd Tassi & Co. Calcivis High-Tech-Gruenderfonds Management New Science Global Healthcare Fund The Mergermarket Group Cambridge Enterprise Horizon Discovery New Wave Ventures The Pharma Letter Cambridge Enterprise Seed Funds IAG Norgine Ventures Management Limited The Research Network Cambridge Innovation Capital ICMBH North-East Healthcare Investment The SidebySide Partnership Cambridge Medical Robotics Ignite Capital Partners NovellusDx The University of Manchester Cancer Research Technology iMicroQ Novo A/S The Wellcome Trust Capital Cell Immupharma Novo Ventures Tigenix Capital Family Office Imperial Innovations NOXXON Pharma Touchstone Innovations Capital Grand Est. Inbio Ventures Numis Securities Limited Trinity Delta Capricorn Venture Partners Independent O2h Ventures Tusk Therapeutics Carrick Therapeutics INKEF Capital Odgers Berndtson TVM Capital Life Science Catapult Ventures Inositec OION TxCell Celixir Instinctif Partners Oncopeptides UBM Cell and Gene Therapy Catapult Intralinks One Nucleus UCL Cell Medica Inventages Oppilotech UCL Business Cellnovo Invention Capital Associates OrbiMed University of Southampton Censo Biotechnologies Investarget OrbiMed Healthcare Fund Management V-Bio Ventures China BlueSky Ventures / BioCapital Impact Investec Wealth & Investment ORI Fund Ventac Partners Fund Invisio Oxford BioMedica Veryan Medical Chronos Therapeutics IOFIX Ltd. Oxford Impedance Diagnostics Vision Healthcare Consultancy Citigate Dewe Rogerson IP Group Oxford Pharmascience Wellcome Trust CK2 Partners Ltd Iratel Ventures Oxford Technology Wellington Partners Clinigen Isis Innovation Oxford University Innovation Westwicke Partners Clubb Capital J A Kemp Oxon White & Case CMS Cameron McKenna J&J Development Corp. Panakes Partners Widecells Coalesce Product Development JAG Shaw Baker Panmure Gordon & Co. Woerwag Pharma GmbH & Co. Combat Medical Jefferies Papyrus Therapeutics Wren Capital Cooley (UK) LLP Johnson & Johnson Innovation Parkure X-Ventures Coulter Partners Jordi Ho Partners HealthCare Xanthella Covington and Burling JP Morgan Paul Capital Xbrane Biopharma Creabilis Julz Co PBD Biotech Ysios Capital CREO Medical Jupiter Diagnostics Peel Hunt Yuuwa Capital Crescendo Biologics Karolinska Development Peptinnovate Zilico Cresset King’s College London Pfizer Curasight King’s Health Partners & King’s Commer- Pharma Intelligence Curetis cialisation Institute PharmaPhorum 21 CONFERENCE FLOORPLAN

BISHOPSGATE SUITE AND BISHOPSGATE 1&2

REGISTRATIONREGISTRATION

BUZZ STOP B

C WALL OF FAME

BUZZ STOP B

1-2-1 MEDIA

MEETING BUZZ STOP ROOM AA

BROADGATE SUITE AND BROADGATE 1&2

FLOORPLAN KEY

1-2-1 Partnering Room Breakfast and Lunch Station

Informal Networking Points Coffee and Tea Station

PharmaTV Camera Station Restrooms

ASSOCIATE PARTNERS

MEDIA PARTNERS

www.biotechandmoney.com/london

Suite 144, The Business Design Centre, 52 Upper St, London N1 0QH Email: [email protected] Phone: +44 (0) 203 637 5908